September 2

Vientos Property Hosts Large Outcropping Uranium Zone, Catamarca Province, Argentina

Uranium mineralization identified over 1.5 km2 with uranium values up to 1.26 lbs/ton U3O8 (0.053% uranium)

Wealth Minerals Ltd. (the \"Company\" or \"Wealth\") (TSX VENTURE:WML)(FRANKFURT:EJZ) is pleased to announce final results from the initial exploration program at its 100%-owned Vientos property in Catamarca Province, northwest Argentina.

Surface sampling at the Company\'s Vientos property has identified a series of five uranium-bearing exhalative/evaporative horizons at or near-surface. The flat-lying horizons range from 1 to 5 metres in thickness and field mapping has extended these mineralized units over an area in excess of 1.5 square kilometres. Uranium assays of 96 characterization rock samples from across the area averaged 0.23 lbs/ton U3O8 (0.010% uranium), with a maximum uranium value of 1.26 lbs/ton U3O8 (0.053% uranium) (Figure 1). Read more: Wealth Minerals Ltd ( WML )

September 2

Nayarit Gold Announces Appointment of Mr. Hall Stewart as Vice President of Exploration

Nayarit Gold Inc. (TSX-V: NYG) is pleased to announce that Mr. Hall Stewart has joined the Company as a Technical Consultant, and on October 6, 2008 will assume the role as Vice President of Exploration.

Mr. Stewart has more than twenty years of experience in exploration and resource development, and an impressive track record of discovery in Mexico. Between 1995 and 2006, Mr. Stewart was involved in discoveries totaling 6.98 million gold-equivalent ounces at the Magistral, Ocampo and Palmarejo projects in Mexico. Mr. Stewart\'s work was instrumental in the discovery and development of the Palmarejo and Guadalupe deposits which were sold to Coeur d\'Alene Mines Corp. for $1.1 Billion dollars. Read more: Nayarit Gold Inc ( NYG )

September 2

Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

Oncolytics Biotech Inc. (\"Oncolytics\") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

\"In this era of personalized cancer treatment, we are quite excited about this trial,\" said Dr. Villalona-Calero. \"Although we have had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potential to target K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy.\" Read more: Oncolytics Biotech Inc ( ONC )

September 2

Platinum Group Metals to Increase Its Interest in Project 1 Platinum Mine From 37% to 74%

Platinum Group Metals Ltd. (\"Platinum Group\") (TSX: PTM)(AMEX: PLG) announces that it has agreed to a term sheet with Anglo Platinum Limited (\"Anglo Platinum\") and Wesizwe Platinum Limited (\"Wesizwe\") to consolidate and rationalize the Western Bushveld Joint Venture (\"WBJV\"). Under the terms Platinum Group will control 74% of the WBJV Projects 1 and 3 and Wesizwe will control 100% of Project 2 and 26% of Projects 1 and 3. The term sheet is subject to regulatory and other approvals and the completion of definitive agreements.

Anglo Platinum will convert its direct WBJV holdings to shares in Wesizwe (WEZ-JSE) in an empowerment transaction. As a result of the proposed transaction, Platinum Group pays no new cash or shares until up to six months after closing. Projects 1 and 3 will be operated by Platinum Group and Wesizwe will operate their core project. Read more: Platinum Group Metals Ltd ( PTM )